Literature DB >> 29444279

Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis.

Elena V Daoud1, Veena Rajaram1, Chunyu Cai1, Robert J Oberle2, Gregory R Martin3, Jack M Raisanen1, Charles L White1, Chan Foong1, Bruce E Mickey4, Edward Pan5, Kimmo J Hatanpaa1.   

Abstract

Adult brainstem gliomas are difficult to classify based on radiologic and histologic features. A K27M mutation in histone 3 has been described to identify high-grade midline gliomas associated with a particularly unfavorable prognosis. While initially considered a pediatric entity, it is now known that H3K27M-mutant brainstem gliomas occur in all age groups, but they are less well understood in adults. We studied clinical, radiologic, and pathologic features of 25 brainstem gliomas diagnosed at our institution between 1994 and 2017 in subjects at least 18 years old. Seven tumors (28%) were positive for the H3K27M mutation, and their median overall survival was significantly shorter than in the H3-wildtype group (p = 0.004). Although the mutation was invariably associated with a poor prognosis, our study also illustrates the radiologic and pathologic heterogeneity in this molecular tumor subtype. The results showed that H3K27M-mutant status and clinically aggressive course cannot be ruled out based on low-grade histology on the initial biopsy, exophytic growth, only focal or minimal enhancement or an extrapontine location, such as midbrain or medulla. These results favor an integrated approach employing a combination of clinical, radiologic, histologic features as well as H3K27M immunohistochemistry for the diagnostic subclassification of adult brainstem gliomas.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29444279     DOI: 10.1093/jnen/nly006

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  22 in total

Review 1.  Targeted Therapies for the Treatment of Glioblastoma in Adults.

Authors:  Ding Fang Chuang; Xuling Lin
Journal:  Curr Oncol Rep       Date:  2019-05-17       Impact factor: 5.075

2.  Automated machine learning based on radiomics features predicts H3 K27M mutation in midline gliomas of the brain.

Authors:  Xiaorui Su; Ni Chen; Huaiqiang Sun; Yanhui Liu; Xibiao Yang; Weina Wang; Simin Zhang; Qiaoyue Tan; Jingkai Su; Qiyong Gong; Qiang Yue
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

3.  Prediction of H3K27M-mutant brainstem glioma by amide proton transfer-weighted imaging and its derived radiomics.

Authors:  Zhizheng Zhuo; Liying Qu; Peng Zhang; Liwei Zhang; Yaou Liu; Yunyun Duan; Dan Cheng; Xiaolu Xu; Ting Sun; Jinli Ding; Cong Xie; Xing Liu; Sven Haller; Frederik Barkhof
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-16       Impact factor: 9.236

4.  Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.

Authors:  Antonio Dono; Takeshi Takayasu; Leomar Y Ballester; Yoshua Esquenazi
Journal:  J Clin Neurosci       Date:  2020-11-01       Impact factor: 1.961

5.  Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness.

Authors:  Vivek Tiwari; Elena V Daoud; Kimmo J Hatanpaa; Ang Gao; Song Zhang; Zhongxu An; Sandeep K Ganji; Jack M Raisanen; Cheryl M Lewis; Pegah Askari; Jeannie Baxter; Michael Levy; Ivan Dimitrov; Binu P Thomas; Marco C Pinho; Christopher J Madden; Edward Pan; Toral R Patel; Ralph J DeBerardinis; A Dean Sherry; Bruce E Mickey; Craig R Malloy; Elizabeth A Maher; Changho Choi
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

Review 6.  Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.

Authors:  Carlos Axel López-Pérez; Xochitl Franco-Mojica; Ricardo Villanueva-Gaona; Alexandra Díaz-Alba; Marco Antonio Rodríguez-Florido; Victor Garcia Navarro
Journal:  J Neurooncol       Date:  2022-05-14       Impact factor: 4.130

7.  Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.

Authors:  Stéphan Grimaldi; Vincent Harlay; Romain Appay; Céline Bequet; Grégorio Petrirena; Chantal Campello; Maryline Barrié; Didier Autran; Sébastien Boissonneau; Thomas Graillon; Dominique Figarella-Branger; Isabelle Nanni; Olivier Chinot; Emeline Tabouret
Journal:  J Neurooncol       Date:  2022-01-07       Impact factor: 4.130

8.  A curious case of T2-FLAIR mismatch in H3K27M mutant glioma.

Authors:  William L Valentino; Darren Okada; Shiv Bhanu
Journal:  Radiol Case Rep       Date:  2022-06-17

9.  Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.

Authors:  Andrew B Lassman; Juan Manuel Sepúlveda-Sánchez; Timothy F Cloughesy; Miguel J Gil-Gil; Vinay K Puduvalli; Jeffrey J Raizer; Filip Y F De Vos; Patrick Y Wen; Nicholas A Butowski; Paul M J Clement; Morris D Groves; Cristóbal Belda-Iniesta; Pierre Giglio; Harris S Soifer; Steven Rowsey; Cindy Xu; Francesca Avogadri; Ge Wei; Susan Moran; Patrick Roth
Journal:  Clin Cancer Res       Date:  2022-06-01       Impact factor: 13.801

10.  Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults.

Authors:  Stefanie Thust; Caroline Micallef; Sachi Okuchi; Sebastian Brandner; Atul Kumar; Kshitij Mankad; Stephen Wastling; Laura Mancini; Hans Rolf Jäger; Ananth Shankar
Journal:  Quant Imaging Med Surg       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.